CME Group Inc. (NASDAQ:CME) Shares Sold by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. lowered its position in shares of CME Group Inc. (NASDAQ:CME) by 1.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 65,580 shares of the financial services provider’s stock after selling 1,089 shares during the period. Pittenger & Anderson Inc.’s holdings in CME Group were worth $14,470,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Capital International Investors grew its position in CME Group by 24.1% in the 1st quarter. Capital International Investors now owns 15,809,175 shares of the financial services provider’s stock worth $3,403,557,000 after purchasing an additional 3,069,806 shares during the last quarter. PineStone Asset Management Inc. grew its holdings in CME Group by 137.6% in the 2nd quarter. PineStone Asset Management Inc. now owns 2,260,644 shares of the financial services provider’s stock worth $444,443,000 after buying an additional 1,309,097 shares in the last quarter. M&G Plc bought a new position in CME Group in the 1st quarter worth approximately $156,631,000. Assenagon Asset Management S.A. increased its position in CME Group by 577.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 645,330 shares of the financial services provider’s stock valued at $126,872,000 after acquiring an additional 550,133 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in CME Group by 11.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,283,196 shares of the financial services provider’s stock valued at $1,038,676,000 after acquiring an additional 537,758 shares in the last quarter. Institutional investors and hedge funds own 87.75% of the company’s stock.

CME Group Stock Down 0.2 %

Shares of CME Group stock opened at $223.08 on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.09. CME Group Inc. has a 12-month low of $190.70 and a 12-month high of $230.36. The firm has a market capitalization of $80.33 billion, a PE ratio of 23.46, a price-to-earnings-growth ratio of 5.62 and a beta of 0.55. The stock’s fifty day moving average is $220.98 and its 200-day moving average is $209.58.

CME Group (NASDAQ:CME) last posted its quarterly earnings data on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.03. CME Group had a return on equity of 13.39% and a net margin of 57.34%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the previous year, the company earned $2.25 EPS. The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. Equities analysts anticipate that CME Group Inc. will post 10.23 earnings per share for the current year.

CME Group Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 25th. Shareholders of record on Monday, September 9th were given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.06%. The ex-dividend date was Monday, September 9th. CME Group’s payout ratio is 48.37%.

Insider Buying and Selling at CME Group

In related news, Director Bryan T. Durkin sold 7,593 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the transaction, the director now directly owns 55,607 shares of the company’s stock, valued at approximately $11,932,706.13. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Bryan T. Durkin sold 7,593 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the transaction, the director now directly owns 55,607 shares of the company’s stock, valued at approximately $11,932,706.13. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Lynne Fitzpatrick sold 754 shares of the stock in a transaction that occurred on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total transaction of $163,610.46. Following the completion of the sale, the chief financial officer now owns 13,261 shares of the company’s stock, valued at approximately $2,877,504.39. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,621 shares of company stock valued at $3,441,063 in the last three months. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CME shares. Morgan Stanley lifted their price objective on shares of CME Group from $210.00 to $233.00 and gave the company an “equal weight” rating in a research note on Thursday, October 17th. Redburn Atlantic downgraded shares of CME Group from a “buy” rating to a “neutral” rating and set a $244.00 price target on the stock. in a research report on Tuesday, October 8th. Piper Sandler upped their price target on shares of CME Group from $240.00 to $250.00 and gave the stock an “overweight” rating in a research note on Monday, October 28th. TD Cowen began coverage on shares of CME Group in a research note on Thursday, September 26th. They set a “hold” rating and a $221.00 price objective on the stock. Finally, Keefe, Bruyette & Woods increased their price target on CME Group from $212.00 to $213.00 and gave the company a “market perform” rating in a research note on Thursday, July 25th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, CME Group presently has a consensus rating of “Hold” and an average target price of $222.73.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.